The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: A propensity score matching analysis

International Journal of Hematology

Volumn 89, Issue 3, 2009, Pages 326-331

  Nishimori, Hisakazu ^a   Matsuo, Keitaro ^b   Maeda, Yoshinobu ^a   Nawa, Yuichiro ^c   Sunami, Kazutaka ^d   Togitani, Kazuto ^e   Takimoto, Hidetaka ^f   Hiramatsu, Yasushi ^g   Kiguchi, Toru ^h   Yano, Tomofumi ⁱ   Yamane, Hiromichi ^j   Tabayashi, Takayuki ^k   Takeuchi, Makoto ^l   Makita, Masanori ^m   Sezaki, Nobuo ⁿ   Yamasuji, Yoshiko ^a   Sugiyama, Haruko ^a   Tabuchi, Takahiro ^a   Kataoka, Itaru ^a   Fujii, Nobuharu ^a   Ishimaru, Fumihiko ^a   Shinagawa, Katsuji ^a   Ikeda, Kazuma ^a   Hara, Masamichi ^c   Yoshino, Tadashi ^a   Tanimoto, Mitsune ^a   more..

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION   (Japan)

^e KOCHI MEDICAL SCHOOL   (Japan)

^f Kochi Medical Center   (Japan)

^g NISHI KOBE MEDICAL CENTER   (Japan)

^h KAGAWA ROSAI HOSPITAL   (Japan)

ⁱ OKAYAMA ROSAI HOSPITAL   (Japan)

^j Sumitomo Besshi Hospital   (Japan)

^k CHUGOKU CENTRAL HOSPITAL   (Japan)

^l Department of Internal Medicine   (Japan)

^m SAISEIKAI NAKATSU HOSPITAL   (Japan)

ⁿ Kure Kyosai Hospital   (Japan)

more..

Author keywords

CHOP; DLBCL; Non Hodgkin's lymphoma; Rituximab; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; JAPAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; SCORING SYSTEM; TREATMENT OUTCOME; DISEASE COURSE; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; JAPAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 67649159580     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0259-8     Document Type: Article

References (25)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89:3909-18.
2. EM McKelvey JA Gottlieb HE Wilson A Haut RW Talley R Stephens 1976 Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma Cancer 38 1484 1493 10.1002/1097-0142(197610)38:4<1484::AID- CNCR2820380407>3.0.CO;2-I
3. RI Fisher ER Gaynor S Dahlberg MM Oken TM Grogan EM Mize 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1002 1006 10.1056/ NEJM199304083281404 (Pubitemid 23095683)
4. LI Gordon D Harrington J Andersen J Colgan J Glick R Neiman 1992 Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma N Engl J Med 327 1342 1349
5. ME Reff K Carner KS Chambers PC Chinn JE Leonard R Raab 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445
6. K Tobinai T Igarashi K Itoh Y Kobayashi M Taniwaki M Ogura 2004 Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma Ann Oncol 15 821 830 10.1093/annonc/mdh176 (Pubitemid 38714746)
7. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825 2833
8. JM Vose BK Link ML Grossbard M Czuczman A Grillo-Lopez P Gilman 2001 Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol 19 389 397
9. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235 242 10.1056/NEJMoa011795 (Pubitemid 34438862)
10. M Pfreundschuh L Trumper A Osterborg R Pettengell M Trneny K Imrie 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379 391 10.1016/S1470-2045(06)70664-7
11. P Feugier A Van Hoof C Sebban P Solal-Celigny R Bouabdallah C Ferme 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 23 4117 4126 10.1200/JCO.2005.09.131 (Pubitemid 46211317)
12. F Matsuyama S Fukuhara S Oguma R Amakawa S Tanabe I Kato 1992 Geographical aspects of bcl-2 gene involvement in Japanese patients with non-Hodgkin's B-cell lymphomas Int J Hematol 55 71 79
13. M Yasukawa S Bando G Dolken E Sada Y Yakushijin S Fujita 2001 Low frequency of BCL-2/J(H) translocation in peripheral blood lymphocytes of healthy Japanese individuals Blood 98 486 488 10.1182/blood.V98.2.486
14. Y Hirose Y Masaki H Karasawa K Shimoyama T Fukushima H Kawabata 2005 Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry Int J Hematol 81 48 57 10.1532/IJH97.04102 (Pubitemid 40165424)
15. JH Paik YK Jeon SS Park YA Kim JE Kim J Huh 2005 Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas Histopathology 47 281 291 10.1111/j.1365-2559.2005.02222.x (Pubitemid 41243266)
16. P Rojnuckarin T Assanasen A Chotipuech P Ruangvejvorachai M Tansatit P Wannakrairot 2007 High frequency of BCL2 translocation in Thai patients with follicular lymphomas Int J Hematol 86 352 357 10.1532/IJH97.A20709
17. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-94. doi: 10.1056/NEJM199309303291402. (Pubitemid 23307906)
18. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
19. PR Rosenbaum DB Rubin 1983 The central role of the propensity score in observational studies for causal effects Biometrika 70 41 55 10.1093/biomet/70.1.41
20. MM Joffe PR Rosenbaum 1999 Invited commentary: propensity scores Am J Epidemiol 150 327 333
21. SO Becker A Ichino 2002 Estimation of average treatment effects based on propensity score Stata J 2 358 377
22. E Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
23. N Mantel 1966 Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 163 170
24. LH Sehn J Donaldson M Chhanabhai C Fitzgerald K Gill R Klasa 2005 Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 5027 5033 10.1200/JCO.2005.09.137 (Pubitemid 46224009)
25. YH Park JJ Lee MH Ryu SY Kim DH Kim YR Do 2006 Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients Ann Hematol 85 257 262 10.1007/s00277-005-0050-8 (Pubitemid 43732650)